Ology Bioservices, Inc. Will Receive $9 Million of Funding to Support Manufacturing of Nipah Virus Vaccine

The Coalition for Epidemic Preparedness Innovations (CEPI)  will provide $43.6 million to advance the development and manufacture of the rVSV-Nipah vaccine candidate against the Nipah virus. UF startup Ology Bioservices, Inc., a biologics contract development and manufacturing organization (CDMO), will receive $9M to support the manufacturing and stockpiling of the rVSV-Nipah vaccine.

The Nipah virus, which can be transmitted from animals to humans and via contaminated food, causes fever, headache, dizziness, vomiting, and severe encephalitis. No vaccine is available, and the illness has a 95 percent fatality rate. CEPI will fund rVSV-Nipah’s pre-clinical, clinical advancement through Phase 2 clinical study, and manufacturing and establishment of an investigational stockpile of the vaccine candidate.

Learn more about Ology Bioservices, Inc. Will Receive $9 Million of Funding to Support Manufacturing of Nipah Virus Vaccine.